nhs_sign

NHS in Scotland makes rheumatoid arthritis drug available

pharmafile | September 14, 2021 | News story | Manufacturing and Production Galapagos UK, NHS, Scotland, filgotinib, rheumatoid arthritis 

The Scottish Medicines Consortium (SMC) have recommended the use of Galapagos UK’s JYSELECA® (filgotinib) for eligible patients with severe active rheumatoid arthritis (RA). The once-daily oral drug is now available across Scotland on the NHS.

Filgotinib was shown to significantly increase the proportion of RA patients going into remission. Across the Phase III studies the drug improved the chance of disease remission, noting a DAS28-CRP score of <2.6, which indicates few or no symptoms.

RA, a degenerative autoimmune disease, affects more than 35,000 people in Scotland, with around 11,000 of those living with server disease activity – chronically impacting a patient’s life. The availability of filgotinib on the NHS will ensure that more people have a chance of slowing the long-term pain and damage of RA.

Read: NICE release new guidance on rheumatoid arthritis treatment

Read: NICE recommends rheumatoid arthritis drug Jyseleca for NHS use

The drug is only licenced for use on those on patients with severe active RA, and not currently for those with moderate symptoms. Galapagos UK are in talks with the SMC to bring access of filgotinib for patients with moderate RA, which will align it with the rest of the UK.

Galapagos UK’s General Manager, Emma Chaffin, said, “We believe this is important news for thousands of people living with this devasting condition.

“We are also mindful that people with moderate rheumatoid arthritis will unfortunately not have the same level of access to filgotinib in Scotland as they currently do elsewhere in the UK, where the NICE issued guidance for use in moderate patients.”

Dr Neil McKay, Consultant Rheumatologist at NHS Lothian, said, “It affects multiple joints causing pain, stiffness and disability. It can also cause disabling fatigue. Modern management requires a prompt referral, early diagnosis and intensive management.

“Yet some people with RA require targeted combination therapy to control their condition. Having access to an advanced targeted therapy like filgotinib, at a relatively early stage, is an important and welcome step forward for people with RA.”

Related Content

weight-2036971_960_720

UK plans £40m drug trial for Novo Nordisk’s Wegovy to aid NHS in treating obesity

The UK Government has announced plans to launch a pilot programme which will provide GPs …

Report finds NHS may miss out on new drugs due to rising costs

Figures from a team at the University of York, the London School of Economics and …

NICE approves first treatment for obstructive HCM for NHS use

The National Institute for Health and Care Excellence (NICE) has announced that it has approved …

Latest content